Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Troriluzole, Placebo for BHV-4157 capsules, 100mg, 140mg, Troriluzole
Pharma Mar S.A.
Obsessive Compulsive Disorder
1 trial -
Troriluzole, Troriluzole
Pharma Mar S.A.
Obsessive Compulsive Disorder
1 trial -
UGN-102 (Mitomycin)
Pharma Mar S.A.
Non-Muscle Invasive Bladder Cancer
1 trial -
UGN-103 (Mitomycin)
Pharma Mar S.A.
Nonmuscle Invasive Bladder Cancer
1 trial -
UGN-104
Pharma Mar S.A.
Low-grade Upper Tract Urothelial Cancer
1 trial -
VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB
Pharma Mar S.A.
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
1 trial -
Venofer 20 mg iron / ml, solution for injection or concentrate for solution for infusion., Ferumoxytol
Pharma Mar S.A.
Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)
1 trial -
Venofer 20 mg iron / ml, solution for injection or concentrate for solution for infusion., Ferumoxytol
Pharma Mar S.A.
Iron Deficiency Anemia (IDA)
1 trial -
Vibegron, Vibegron, Vibegron, Vibegron, Vibegron, Vibegron, Vibegron
Pharma Mar S.A.
Neurogenic Detrusor Overactivity (NDO)
1 trial -
Viltolarsen
Pharma Mar S.A.
Duchenne Muscular Dystrophy (DMD)
1 trial -
Xylocore Medium Strength, bicaVera 4,25 % Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, Xylocore High Strength, PHYSIONEAL 40 Glucose 3,86 % w/v / 38,6 mg/ml, Peritonealdialyselösung, balance 4,25% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL 35 Glucose 1,36 % w/v / 13,6 mg/ml, Peritonealdialyselösung, FIXIONEAL “35 Glucosio 3,86% p/v/38,6 mg/ml” in sacca Clear-Flex Soluzione per dialisi peritoneale, balance 2,3% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL
Pharma Mar S.A.
End-Stage Kidney Disease
1 trial -
YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion
Pharma Mar S.A.
Relapsed/Refractory Follicular Lymphoma
1 trial -
ZYTIGA 250 mg tablets, ZYTIGA 500 mg film-coated tablets, Apalutamide placebo, JNJ-56021927, PREDNISONE, -
Pharma Mar S.A.
Castration-Resistant Prostate Cancer
1 trial -
Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Zilbrysq 32.4 mg solution for injection in pre-filled syringe
Pharma Mar S.A.
Generalized Myasthenia Gravis
1 trial -
Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilbrysq 16.6 mg solution for injection in pre-filled syringe
Pharma Mar S.A.
Generalized Myasthenia Gravis
1 trial -
Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe
Pharma Mar S.A.
Generalized Myasthenia Gravis
1 trial -
Zilucoplan sodium
Pharma Mar S.A.
Generalized Myasthenia Gravis
1 trial -
Zovirax 50 mg/g crema, Lipovir 50 mg/g Gel, Placebo
Pharma Mar S.A.
Recurrent herpes labialis (RHL)
1 trial -
Zydelig 100 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Truxima 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Zydelig 100 mg film-coated tablets, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer I
Pharma Mar S.A.
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
alprazolam, Placebo matching Staccato® alprazolam and without active substance
Pharma Mar S.A.
Treatment of stereotypical prolonged seizure
1 trial -
bimekizumab
Pharma Mar S.A.
Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis
1 trial -
bimekizumab
Pharma Mar S.A.
Psoriatic Arthritis
1 trial -
bimekizumab
Pharma Mar S.A.
Hidradenitis Suppurativa
1 trial -
bimekizumab
Pharma Mar S.A.
Hidradenitis Suppurativa
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources